GlassScriptPhysician profile
Indumathi R Baskar
NPI 1083634331
$5,735.89
in general payments reported to CMS, 2019-2025
37 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $372 · 2021: $1,026 · 2022: $566 · 2023: $669 · 2024: $1,288 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,327 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.23 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.54 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $515.10 | 2019-2025 | |
| Amgen INC. | $495.73 | 2019-2025 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $423.83 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $416.58 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $357.41 | 2022-2025 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $335.47 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $229.03 | 2019-2022 | |
| Allergan, INC. | $220.12 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $214.06 | 2024-2025 | Contrave |
| Astrazeneca Pharmaceuticals LP | $197.53 | 2019-2025 | Airsupra, Breztri, Saphnelo |
| Bayer Healthcare Pharmaceuticals INC. | $112.55 | 2022-2025 | |
| Lilly USA, LLC | $97.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $87.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $75.44 | 2024-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indumathi Baskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.